Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Mendelian randomization

George Thanassoulis, MD
Christopher J O'Donnell, MD, MPH
Section Editor
Benjamin A Raby, MD, MPH
Deputy Editor
Jennifer S Tirnauer, MD


Mendelian randomization represents a novel epidemiologic study design that incorporates genetic information into traditional epidemiologic methods. Studies based on Mendelian randomization will likely become increasingly common as genetic knowledge of health and disease expands with data from genomewide association studies and genome sequencing. Mendelian randomization provides an approach to addressing questions of causality without many of the typical biases that impact the validity of traditional epidemiologic approaches.

While Mendelian randomization studies can provide important suggestive evidence for causal relations between risk factor and disease outcome, they are not true experiments and are dependent on several assumptions. Evidence from randomized controlled trials, when possible, should continue to guide clinical decisions.

This topic will discuss the rationale and limitations of Mendelian randomization as a study design. The principles of Mendelian inheritance, which are the basis for randomization of this study design, are discussed separately. (See "Overview of Mendelian inheritance".)


The Mendelian randomization design was first proposed in 1986 to evaluate whether low levels of LDL cholesterol increase cancer risk [1]. Observational studies had reported a higher risk of cancer in individuals with low LDL levels, compared with subjects with normal or elevated LDL levels. However, biases implicit in observational studies could not be excluded as an explanation for the observed association.

Investigators proposed a natural experiment, suggesting that the effect of low LDL levels on cancer risk could be determined by comparing cancer rates in individuals with and without genotypes that predispose to low LDL level. The inheritance of a particular genotype, based on Mendel’s second law of independent assortment, was far less likely to be influenced by lifestyle or environmental issues than LDL levels themselves. This hypothetical study, finally performed more than 20 years later when genetic data became more readily available, found no increased risk among individuals with lifelong low LDL levels [2].  


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Feb 2017. | This topic last updated: Tue Jul 14 00:00:00 GMT 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Katan MB. Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet 1986; 1:507.
  2. Trompet S, Jukema JW, Katan MB, et al. Apolipoprotein e genotype, plasma cholesterol, and cancer: a Mendelian randomization study. Am J Epidemiol 2009; 170:1415.
  3. Greenland S, Morgenstern H. Confounding in health research. Annu Rev Public Health 2001; 22:189.
  4. Lawlor DA, Harbord RM, Sterne JA, et al. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 2008; 27:1133.
  5. Didelez V, Sheehan N. Mendelian randomization as an instrumental variable approach to causal inference. Stat Methods Med Res 2007; 16:309.
  6. Kaul S, Diamond GA. Trial and error. How to avoid commonly encountered limitations of published clinical trials. J Am Coll Cardiol 2010; 55:415.
  7. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? N Engl J Med 2000; 342:1907.
  8. Stone GW, Pocock SJ. Randomized trials, statistics, and clinical inference. J Am Coll Cardiol 2010; 55:428.
  9. Liberopoulos G, Trikalinos NA, Ioannidis JP. The elderly were under-represented in osteoarthritis clinical trials. J Clin Epidemiol 2009; 62:1218.
  10. Thanassoulis G, O'Donnell CJ. Mendelian randomization: nature's randomized trial in the post-genome era. JAMA 2009; 301:2386.
  11. Newhouse JP, McClellan M. Econometrics in outcomes research: the use of instrumental variables. Annu Rev Public Health 1998; 19:17.
  12. Morgan TM, Krumholz HM, Lifton RP, Spertus JA. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA 2007; 297:1551.
  13. Lawlor DA, Windmeijer F, Smith GD. Is Mendelian randomization 'lost in translation?': comments on 'Mendelian randomization equals instrumental variable analysis with genetic instruments' by Wehby et al. Stat Med 2008; 27:2750.
  14. Devlin B, Roeder K. Genomic control for association studies. Biometrics 1999; 55:997.
  15. Price AL, Patterson NJ, Plenge RM, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38:904.
  16. Rutherford SL. From genotype to phenotype: buffering mechanisms and the storage of genetic information. Bioessays 2000; 22:1095.
  17. Palmer TM, Lawlor DA, Harbord RM, et al. Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med Res 2012; 21:223.
  18. Bennet A, Di Angelantonio E, Erqou S, et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med 2008; 168:598.
  19. Chasman DI, Shiffman D, Zee RY, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis 2009; 203:371.
  20. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102:1082.
  21. Holmer SR, Hengstenberg C, Kraft HG, et al. Association of polymorphisms of the apolipoprotein(a) gene with lipoprotein(a) levels and myocardial infarction. Circulation 2003; 107:696.
  22. Kronenberg F, Kronenberg MF, Kiechl S, et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 1999; 100:1154.
  23. Luc G, Bard JM, Arveiler D, et al. Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis 2002; 163:377.
  24. Luke MM, Kane JP, Liu DM, et al. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol 2007; 27:2030.
  25. Shiffman D, O'Meara ES, Bare LA, et al. Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2008; 28:173.
  26. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009; 301:2331.
  27. Boerwinkle E, Leffert CC, Lin J, et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992; 90:52.
  28. Zacho J, Tybjaerg-Hansen A, Jensen JS, et al. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008; 359:1897.
  29. Elliott P, Chambers JC, Zhang W, et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009; 302:37.
  30. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012; 380:572.